The EGFR is also a main therapeutic target in lung cancer, since it is frequently overexpressed, exhibits amended signaling or is mutated in non-small cell lung cancer (NSCLC) [1,18,19,20]. This evidence concerns the gene EGFR and lung carcinoma.